Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Lyra Therapeutics, Inc. (LYRA) had Weighted-Average Shares Outstanding (Diluted) of 49.80M for the most recently reported fiscal quarter, ending 2023-12-31.
| Income Statement Financials | |
$0.15M |
|
$-15.16M |
|
-- |
|
$0.15M |
|
$16.62M |
|
$-16.48M |
|
$1.34M |
|
$-15.14M |
|
$-15.14M |
|
$-15.16M |
|
$-15.16M |
|
$-15.16M |
|
$-15.16M |
|
$-16.48M |
|
$-17.48M |
|
49.80M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
49.80M |
$-0.19 |
|
$-0.19 |
|
| Balance Sheet Financials | |
$104.82M |
|
$2.04M |
|
$37.78M |
|
$142.60M |
|
$19.60M |
|
-- |
|
$33.58M |
|
$53.18M |
|
$89.42M |
|
$89.42M |
|
$89.42M |
|
57.22M |
|
| Cash Flow Statement Financials | |
$-63.30M |
|
$-12.58M |
|
$65.69M |
|
$33.94M |
|
$23.75M |
|
$-10.20M |
|
$5.89M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.35 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-11285.62% |
|
-11285.63% |
|
-- |
|
-10369.18% |
|
-10380.83% |
|
$-64.35M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-16.95% |
|
-16.95% |
|
-10.63% |
|
-16.95% |
|
$1.56 |
|
$-1.29 |
|
$-1.27 |
|